The significance of rebiopsy in the diagnosis of prostate cancer;Stellenwert der rebiopsie in der diagnostik des prostatakarzinoms

Urologe - Ausgabe A

Volumn 48, Issue 2, 2009, Pages 163-169

  Braun, K P ^a,b,d   Brookman Amissah, S ^c   May, M ^c   Grassmel, Y ^c   Heintze, C ^a   Hoschke, B ^c   Braun, V ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Praxis für Allgemeinmedizin   (Germany)

^c CTK   (Germany)

^d NONE   (Germany)

Author keywords

Prostate cancer; PSA; PSA velocity; Rebiopsy; Ultrasound guided transrectal biopsy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ANTIGEN SPECIFICITY; ARTICLE; CANCER CLASSIFICATION; CANCER CYTODIAGNOSIS; CANCER GRADING; CANCER PATIENT; CANCER STAGING; DEMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FOLLOW UP; GLEASON SCORE; HUMAN; HUMAN TISSUE; IATROGENIC DISEASE; MAJOR CLINICAL STUDY; MALE; PATIENT INFORMATION; PROSTATE BIOPSY; PROSTATE CANCER; RECTUM BIOPSY; RETROSPECTIVE STUDY; TISSUE SECTION; XENOTRANSPLANTATION;

ADULT; AGED; BIOPSY, NEEDLE; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; REOPERATION; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 60549094596     PISSN: 03402592     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00120-008-1860-9     Document Type: Article

References (19)

1. Andriole 2005 J Natl Cancer Inst 97 433
2. Braun 2007 Int Urol Nephrol 39 1125
3. Catalona 2006 Ann Intern Med 144 441
4. Deutsche Krebsgesellschaft. EBM-Leitlinie PSA-Bestimmung in der Protatakazinomdiagnostik. Version 1.0, Stand: 13.September 2002
5. Edwards 2005 J Natl Cancer Inst 97 1407
6. Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. (2006) In Zusammenarbeit mit dem Robert Koch Institut. Krebs in Deutschland Häufigkeit und Trends, 5. überarbeitete, aktualisierte Aufl. Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V., Lübeck, S 68
7. Haas 2007 J Natl Cancer Inst 99 1484
8. Kataja 2005 Ann Oncol 16 i34
9. Keetch 1994 J Urol 151 1571
10. Loeb 2007 J Urol 178 2348
11. NCCN (2008) Clinical practice guidelines in oncology. NCCN, http://www.nccn.org
12. Okegawa 2003 Int J Urol 10 201
13. Perachino 1997 Eur Urol 32 155
14. Roberts 2002 Urology 59 79
15. Roehl 2002 J Urol 167 2435
16. Schroder 1998 J Natl Cancer Inst 90 1817
17. Taneja 2003 Rev Urol Summer 5 149
18. Welch HG, Fisher ES, Gottlieb DJ, Barry MJ (2007) Detection of prostate cancer via biopsy in the Medicare-SEER population during the PSA era. J Natl Cancer Inst 19;99(18): 1395-1400
19. Wolters T, Roobol MJ, Bangma CH, Schröder FH (2008) Is prostate-specific antigen velocity selective for clinically significant prostate cancer in screening? European randomized study of screening for prostate cancer (Rotterdam). Eur Urol (Epub ahead of print)